$108.35
+0.16
(+0.15%)▲
Live
1.15%
Downside
Day's Volatility :4.28%
Upside
3.16%
24.25%
Downside
52 Weeks Volatility :43.03%
Upside
24.79%
Period | Mesa Laboratories Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 4.85% | 6.5% | 0.0% |
6 Months | 13.87% | 7.1% | 0.0% |
1 Year | -18.66% | 9.8% | 0.0% |
3 Years | -61.94% | 14.2% | -20.2% |
Market Capitalization | 586.7M |
Book Value | $26.95 |
Dividend Share | 0.64 |
Dividend Yield | 0.59% |
Earnings Per Share (EPS) | -47.2 |
PEG Ratio | 0.0 |
Wall Street Target Price | 118.0 |
Profit Margin | -117.61% |
Operating Margin TTM | 4.74% |
Return On Assets TTM | 0.42% |
Return On Equity TTM | -94.36% |
Revenue TTM | 216.2M |
Revenue Per Share TTM | 40.14 |
Quarterly Revenue Growth YOY | 6.0% |
Gross Profit TTM | 116.6M |
EBITDA | 35.3M |
Diluted Eps TTM | -47.2 |
Quarterly Earnings Growth YOY | 3.88 |
EPS Estimate Current Year | -0.05 |
EPS Estimate Next Year | 0.37 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 8.91%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 103.1M | ↑ 7.23% |
Net Income | 7.5M | ↓ 352.67% |
Net Profit Margin | 7.26% | ↑ 10.34% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 117.7M | ↑ 14.11% |
Net Income | 1.3M | ↓ 81.97% |
Net Profit Margin | 1.15% | ↓ 6.11% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 133.9M | ↑ 13.81% |
Net Income | 3.3M | ↑ 142.7% |
Net Profit Margin | 2.44% | ↑ 1.29% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 184.3M | ↑ 37.63% |
Net Income | 1.9M | ↓ 42.85% |
Net Profit Margin | 1.01% | ↓ 1.43% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 219.1M | ↑ 18.85% |
Net Income | 930.0K | ↓ 50.29% |
Net Profit Margin | 0.42% | ↓ 0.59% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 216.2M | ↓ 1.32% |
Net Income | -254.2M | ↓ 27438.28% |
Net Profit Margin | -117.6% | ↓ 118.02% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 54.3M | ↓ 7.6% |
Net Income | 451.0K | ↓ 65.47% |
Net Profit Margin | 0.83% | ↓ 1.39% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 55.6M | ↑ 2.4% |
Net Income | 611.0K | ↑ 35.48% |
Net Profit Margin | 1.1% | ↑ 0.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 50.6M | ↓ 8.9% |
Net Income | -549.0K | ↓ 189.85% |
Net Profit Margin | -1.08% | ↓ 2.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 53.2M | ↑ 4.98% |
Net Income | -1.2M | ↑ 124.04% |
Net Profit Margin | -2.31% | ↓ 1.23% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 53.5M | ↑ 0.58% |
Net Income | 2.1M | ↓ 272.03% |
Net Profit Margin | 3.96% | ↑ 6.27% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 58.9M | ↑ 10.16% |
Net Income | -254.6M | ↓ 12131.33% |
Net Profit Margin | -432.2% | ↓ 436.16% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 156.8M | ↓ 4.47% |
Total Liabilities | 45.5M | ↓ 29.79% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 420.2M | ↑ 168.04% |
Total Liabilities | 200.2M | ↑ 340.41% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 600.2M | ↑ 42.82% |
Total Liabilities | 193.9M | ↓ 3.13% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 707.4M | ↑ 17.87% |
Total Liabilities | 313.6M | ↑ 61.7% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 661.8M | ↓ 6.44% |
Total Liabilities | 268.4M | ↓ 14.42% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 444.8M | ↓ 32.8% |
Total Liabilities | 299.4M | ↑ 11.56% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 663.0M | ↑ 1.03% |
Total Liabilities | 275.8M | ↓ 2.2% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 661.8M | ↓ 0.17% |
Total Liabilities | 268.4M | ↓ 2.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 642.6M | ↓ 2.9% |
Total Liabilities | 254.9M | ↓ 5.02% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 637.2M | ↓ 0.84% |
Total Liabilities | 249.4M | ↓ 2.14% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 741.8M | ↑ 16.41% |
Total Liabilities | 338.8M | ↑ 35.83% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 446.8M | ↓ 39.77% |
Total Liabilities | 301.4M | ↓ 11.04% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 30.6M | ↑ 23.13% |
Investing Cash Flow | -3.9M | ↓ 77.42% |
Financing Cash Flow | -21.7M | ↑ 166.93% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 26.6M | ↓ 13.08% |
Investing Cash Flow | -185.6M | ↑ 4683.12% |
Financing Cash Flow | 231.3M | ↓ 1167.17% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 37.1M | ↑ 39.59% |
Investing Cash Flow | -2.0M | ↓ 98.93% |
Financing Cash Flow | 146.2M | ↓ 36.77% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 39.2M | ↑ 5.8% |
Investing Cash Flow | -305.2M | ↑ 15222.54% |
Financing Cash Flow | 52.6M | ↓ 64.05% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 28.0M | ↓ 28.66% |
Investing Cash Flow | -9.5M | ↓ 96.89% |
Financing Cash Flow | -33.3M | ↓ 163.39% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.7M | ↓ 26.89% |
Investing Cash Flow | -6.6M | ↑ 302.93% |
Financing Cash Flow | -8.9M | ↓ 52.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 12.5M | ↑ 62.21% |
Investing Cash Flow | -1.0M | ↓ 84.46% |
Financing Cash Flow | -4.4M | ↓ 50.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.9M | ↓ 20.61% |
Investing Cash Flow | -270.0K | ↓ 73.68% |
Financing Cash Flow | -9.5M | ↑ 116.73% |
Sell
Neutral
Buy
Mesa Laboratories Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Mesa Laboratories Inc | 22.69% | 13.87% | -18.66% | -61.94% | -53.59% |
![]() Teledyne Technologies Inc | 8.18% | -0.78% | 7.18% | -6.58% | 40.35% |
![]() Trimble Navigation Limited | -0.87% | 7.3% | 1.41% | -34.28% | 22.02% |
![]() Fortive Corp | -4.22% | -5.38% | -8.8% | 1.48% | 6.61% |
![]() Garmin Ltd. | 7.59% | 39.01% | 64.17% | 13.12% | 121.48% |
![]() Keysight Technologies, Inc. | -0.01% | -12.85% | -19.59% | -15.06% | 49.66% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Mesa Laboratories Inc | 557.29 | NA | 0.0 | -0.05 | -0.94 | 0.0 | 0.01 | 26.95 |
![]() Teledyne Technologies Inc | 22.6 | 22.6 | 0.98 | 19.4 | 0.1 | 0.05 | NA | 194.97 |
![]() Trimble Navigation Limited | 58.02 | 58.02 | 2.22 | 2.73 | 0.06 | 0.04 | NA | 17.72 |
![]() Fortive Corp | 28.36 | 28.36 | 1.39 | 3.81 | 0.09 | 0.04 | 0.0 | 29.97 |
![]() Garmin Ltd. | 24.38 | 24.38 | 5.62 | 5.72 | 0.2 | 0.09 | 0.02 | 37.73 |
![]() Keysight Technologies, Inc. | 29.45 | 29.45 | 3.0 | 5.94 | 0.17 | 0.08 | NA | 28.13 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Mesa Laboratories Inc | Buy | $586.7M | -53.59% | 557.29 | -117.61% |
![]() Teledyne Technologies Inc | Buy | $19.7B | 40.35% | 22.6 | 15.86% |
![]() Trimble Navigation Limited | Buy | $13.6B | 22.02% | 58.02 | 6.25% |
![]() Fortive Corp | Buy | $24.7B | 6.61% | 28.36 | 14.39% |
![]() Garmin Ltd. | Hold | $33.2B | 121.48% | 24.38 | 24.96% |
![]() Keysight Technologies, Inc. | Buy | $23.6B | 49.66% | 29.45 | 15.71% |
Insights on Mesa Laboratories Inc
Revenue is up for the last 4 quarters, 50.64M → 58.90M (in $), with an average increase of 4.9% per quarter
Netprofit is down for the last 2 quarters, 2.11M → -254.58M (in $), with an average decrease of 12131.3% per quarter
In the last 1 year, Garmin Ltd. has given 64.2% return, outperforming this stock by 82.9%
In the last 3 years, Garmin Ltd. has given 13.1% return, outperforming this stock by 75.0%
BlackRock Inc
Conestoga Capital Advisors, LLC
Vanguard Group Inc
Royce & Associates, LP
Morgan Stanley - Brokerage Accounts
Ranger Investment Management LP
mesa laboratories, inc., develops, manufactures and markets high-quality process validation, monitoring and calibration instruments and consumables worldwide. mesa offers quality data loggers for monitoring temperature, humidity, and pressure and biological indicators (bis) for medical device and pharmaceutical manufacturing sterilization monitoring. the datatrace data loggers and mesa bis are available to monitor and validate applications including steam and eo sterilization, autoclave validation, incubators, heat tunnels and more. mesa’s bi offering also includes bis for industrial use, hydrogen peroxide (h2o2), chlorine dioxide and more. the phoenix meter is a point-of-use dialysate qc meter used prior to each procedure. the 90xl meter is the industry standard for calibration of dialysis machines in the field. also available are industry leading nist-traceable calibration solutions. mesa also offers cap torque testers which are durable, reliable and computerized cap torque analyzers
Organization | Mesa Laboratories Inc |
Employees | 736 |
CEO | Mr. Gary M. Owens |
Industry | Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables |
A Spac I Acquisition Corp
$108.35
+0.15%
Keyarch Acquisition Corp
$108.35
+0.15%
Connexa Sports Technologies Inc
$108.35
+0.15%
Us Value Etf
$108.35
+0.15%
First Wave Biopharma Inc
$108.35
+0.15%
Global X Msci Next Emerging
$108.35
+0.15%
Fat Projects Acquisition Corp
$108.35
+0.15%
Capital Link Global Fintech
$108.35
+0.15%
Applied Uv Inc
$108.35
+0.15%